

“The U.S. Food and Drug Administration on Tuesday gave the nod to the first of a new class of medications against dry eye disease. Xiidra (lifitegrast) eyedrops are a newly developed type of drug called LFA-1 agonists, the agency explained in a news release.”
“Xiidra’s safety and effectiveness was assessed in more than 1,000 adults in four separate clinical trials. Patients received either Xiidra eyedrops or a placebo eyedrop twice daily for three months. According to the FDA, people taking Xiidra gained more improvement in “both the signs and the symptoms of eye dryness” compared to those taking the placebo.Side effects included eye irritation, blurred vision and “an unusual taste sensation,” the FDA said. Xiidra is made by Shire US, of Lexington, Mass.”
Read the full article: FDA Approves First of New Drugs for Dry Eye
Recent Posts
- The American Health Council Appoints Dr. James Bashkin, D.Phil. to the Physician Board March 31, 2020
- The American Health Council Appoints Dr. Robert W. Letton, MD to the Physician Board March 19, 2020
- The American Health Council Appoints Dr. Akwasi Adjei to the Industry Board January 17, 2020
- The American Health Council Appoints Dr. Nelson Leung to the Physician Board January 17, 2020
- The American Health Council Appoints Ms. Karie Soost to the Physician Board January 17, 2020
- The American Health Council Appoints Mr. Gregory King to the Industry Board January 17, 2020